Jason O'Byrne
Known title: EVP & Chief Financial OfficerCIK: 0001871145
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
No recent news for Caribou Biosciences (CRBU). There are no recent news releases specifically about Caribou Biosciences in the past week. The stock remains unchanged in terms of public announcements. Technical indicators show RSI at 35.1 and support around $1.59, but without new information the market context is limited.
Transaction History
| VIR | ▼ Sell | Other | 2,500 | $0 | 3/20/2026 | View on chart |
| VIR | ▼ Sell | Other | 2,500 | $0 | 3/20/2026 | View on chart |
| VIR | ▼ Sell | Open Market | 1,634 | $16K | 2/24/2026 | View on chart |
| VIR | ▼ Sell | Open Market | 2,089 | $16K | 2/23/2026 | View on chart |
| VIR | ▲ Buy | Grant | 55,000 | $0 | 2/22/2026 | View on chart |
| VIR | ▼ Sell | Open Market | 6,799 | $38K | 11/17/2025 | View on chart |
| VIR | ▲ Buy | Grant | 40,000 | $0 | 2/22/2025 | View on chart |
| VIR | ▲ Buy | Grant | 75,000 | $0 | 11/15/2024 | View on chart |
| CRBU | ▲ Buy | Grant | 33,000 | $0 | 2/20/2024 | View on chart |
| CRBU | ▲ Buy | Option Exercise | 24,336 | $100K | 2/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates
Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates. Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.